Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3072% below fair value
$5.89−0.15 (-2.48%)
Close on Nov 12, 2026Market cap $302.00MP/E –Yield –
Emergent BioSolutions gross margin
Gross margin is gross profit as a percentage of revenue.
Emergent BioSolutions's gross margin for the twelve months ending Sep 30, 2026 was 48.4%. For fiscal 2025 it was 56.1%, against 34.7% the year before. The highest annual figure on record is 84.6% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 56.1% | +21.4 |
| FY2024 | Dec 31, 2024 | 34.7% | +4.4 |
| FY2023 | Dec 31, 2023 | 30.3% | −4.0 |
| FY2022 | Dec 31, 2022 | 34.3% | −16.0 |
| FY2021 | Dec 31, 2021 | 50.3% | −8.4 |
| FY2020 | Dec 31, 2020 | 58.7% | −2.1 |
| FY2019 | Dec 31, 2019 | 60.8% | +2.0 |
| FY2018 | Dec 31, 2018 | 58.8% | −7.7 |
| FY2017 | Dec 31, 2017 | 66.5% | −7.6 |
| FY2016 | Dec 31, 2016 | 74.2% | −3.9 |
| FY2015 | Dec 31, 2015 | 78.0% | +3.2 |
| FY2014 | Dec 31, 2014 | 74.8% | −5.3 |
| FY2013 | Dec 31, 2013 | 80.1% | −3.5 |
| FY2012 | Dec 31, 2012 | 83.7% | −0.9 |
| FY2011 | Dec 31, 2011 | 84.6% | +1.0 |
| FY2010 | Dec 31, 2010 | 83.5% | +3.2 |
| FY2009 | Dec 31, 2009 | 80.3% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 26.5% | −36.3 |
| Q2 FY2026 | Jun 30, 2026 | 58.6% | +6.0 |
| Q1 FY2026 | Mar 31, 2026 | 53.9% | −6.3 |
| Q4 FY2025 | Dec 31, 2025 | 42.9% | +3.5 |
| Q3 FY2025 | Sep 30, 2025 | 62.8% | +8.0 |
| Q2 FY2025 | Jun 30, 2025 | 52.5% | +71.4 |
| Q1 FY2025 | Mar 31, 2025 | 60.2% | +11.0 |
| Q4 FY2024 | Dec 31, 2024 | 39.4% | +8.7 |
| Q3 FY2024 | Sep 30, 2024 | 54.9% | +22.6 |
| Q2 FY2024 | Jun 30, 2024 | -18.8% | −60.5 |
| Q1 FY2024 | Mar 31, 2024 | 49.2% | +46.2 |
| Q4 FY2023 | Dec 31, 2023 | 30.7% | −0.4 |
| Q3 FY2023 | Sep 30, 2023 | 32.2% | +0.8 |
| Q2 FY2023 | Jun 30, 2023 | 41.6% | +14.6 |
| Q1 FY2023 | Mar 31, 2023 | 3.0% | −43.6 |
| Q4 FY2022 | Dec 31, 2022 | 31.1% | −27.6 |
| Q3 FY2022 | Sep 30, 2022 | 31.4% | −1.7 |
| Q2 FY2022 | Jun 30, 2022 | 27.0% | −11.2 |
| Q1 FY2022 | Mar 31, 2022 | 46.6% | −12.4 |
| Q4 FY2021 | Dec 31, 2021 | 58.7% | −10.2 |
| Q3 FY2021 | Sep 30, 2021 | 33.0% | −28.3 |
| Q2 FY2021 | Jun 30, 2021 | 38.2% | −28.9 |
| Q1 FY2021 | Mar 31, 2021 | 59.0% | −1.1 |
| Q4 FY2020 | Dec 31, 2020 | 68.9% | +47.3 |
| Q3 FY2020 | Sep 30, 2020 | 61.3% | +38.6 |
| Q2 FY2020 | Jun 30, 2020 | 67.1% | +70.0 |
| Q1 FY2020 | Mar 31, 2020 | 60.1% | +74.4 |
| Q4 FY2019 | Dec 31, 2019 | 21.6% | +17.4 |
| Q3 FY2019 | Sep 30, 2019 | 22.7% | +10.4 |
| Q2 FY2019 | Jun 30, 2019 | -2.9% | −33.2 |
| Q1 FY2019 | Mar 31, 2019 | -14.4% | −6.3 |
| Q4 FY2018 | Dec 31, 2018 | 4.1% | −23.3 |
| Q3 FY2018 | Sep 30, 2018 | 12.3% | −19.7 |
| Q2 FY2018 | Jun 30, 2018 | 30.3% | +21.9 |
| Q1 FY2018 | Mar 31, 2018 | -8.1% | −20.8 |
| Q4 FY2017 | Dec 31, 2017 | 27.4% | −6.2 |
| Q3 FY2017 | Sep 30, 2017 | 32.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 8.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 12.7% | – |
| Q4 FY2016 | Dec 31, 2016 | 33.6% | – |
See a number that looks wrong?